接受新辅助激素治疗的患者，根治性前列腺切除术中手术切缘出现恶性肿瘤的风险降低了近三倍。
The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment.
作者信息
Hugosson J, Abrahamsson P A, Ahlgren G, Aus G, Lundberg S, Schelin S, Schain M, Pedersen K
机构信息
Department of Urology, Göteborg University, Sweden.
出版信息
Eur Urol. 1996;29(4):413-9. doi: 10.1159/000473789.
OBJECTIVES
To investigate the outcome of neo-adjuvant hormone treatment before radical prostatectomy regarding local tumour extension, peri-operative blood loss and operation time.
PATIENTS
Of 111 surgically treated patients with prostate cancer (T1b-T3a, N0, M0, G1-3), 55 were randomised to immediate radical prostatectomy and 56 to 3 months of neo-adjuvant treatment with triptorelin (3.75 mg i.m. every 28 days) and cyproterone acetate (50 mg b.i.d. for 3 weeks to prevent flare).
RESULTS
No differences were found in blood loss or operation time but patients who had neo-adjuvant treatment had a significantly lower frequency of positive margins (41 vs. 23%, p = 0.013).
CONCLUSION
Neo-adjuvant treatment does not facilitate radical prostatectomy but may improve the chance of local cure. This must, however, be documented with long-term follow-up in randomised patients.
目的
探讨根治性前列腺切除术前行新辅助激素治疗对局部肿瘤进展、围手术期失血及手术时间的影响。
患者
111例接受手术治疗的前列腺癌患者（T1b-T3a，N0，M0，G1-3），55例随机接受即刻根治性前列腺切除术，56例接受3个月的新辅助治疗，使用曲普瑞林（每28天肌内注射3.75mg）和醋酸环丙孕酮（每日2次，每次50mg，共3周以预防病情突然加重）。
结果
失血和手术时间方面未发现差异，但接受新辅助治疗的患者切缘阳性率显著降低（41%对23%，p = 0.013）。
结论
新辅助治疗虽无助于根治性前列腺切除术，但可能提高局部治愈的机会。然而，这必须通过对随机分组患者的长期随访来证实。
Zotero 插件